MedTrace Logo

Dexamethasone With TAP Block Increasing the Duration of the Peripheral Nerve Block in Caesarian Section

NCT02440880 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2016-08-03

No results posted yet for this study

Summary

Nowadays Cesarean sections became the most popular surgery worldwide with the consumption of the hospital resources and the continuous need to decrease the costs, work load and medical stuff engagement. One of the most common problem is the need to control pain post operatively, this issue increase the work load over the pain management team and increase lead to patient in satisfaction.

This study will test the usage of dexamethasone with different doses (4 and 8 mg) either locally or intravenously (I.V.) with the local anesthetics in TAP (transversus abdominis plane) block to prolong the duration of the block and decrease the need of post-operative analgesics.

Conditions

Interventions

DRUG

Dexamethasone in addition to TAP block in dose of 4 mg

Dexamethasone in addition to TAP block in dose of 4 mg

DRUG

Dexamethasone in combination with TAP block in dose of 8 mg

Dexamethasone in combination with TAP block in dose of 8 mg

DRUG

Dexamethasone intravenous 4mg+ TAP block

Dexamethasone intravenous in addition to TAP block in dose of 4 mg

DRUG

Dexamethasone intravenous in addition to TAP block in dose of 8 mg

Dexamethasone intravenous + TAP block in dose of 8 mg

OTHER

control

TAP block without Dexamethasone neither intravenous nor in combination with the block

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Hassan Ali, LECTURER · Anesthesia department, faculty of medicine ,Cairo university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-11-30
Completion
2017-01-31

Countries

  • Egypt

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440880 on ClinicalTrials.gov